A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
DOI: https://doi.org/10.2147/JIR.S395231
IF: 4.5
2023-04-06
Journal of Inflammation Research
Abstract:Yalan Yang, 1, &ast Dao Xin, 2, &ast Huike Wang, 1, &ast Lulu Guan, 1 Xiangrui Meng, 1 Taiying Lu, 1 Xiwen Bai, 3 Feng Wang 1 1 Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China; 2 Department of Medical Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 3 Department of Translational Medicine, Nanchang University Queen Mary School, Nanchang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Feng Wang, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China, Email Purpose: Neoadjuvant immunochemotherapy (nICT) for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) has attracted widespread attention recently, whose safety and clinical benefit was observed in clinical researches. This study aimed to develop and validate a novel predictor systemic inflammation-tumor markers index (SITI) to predict the pathological complete response (pCR) for resectable LA-ESCC patients receiving nICT. Patients and Methods: A total of 147 LA-ESCC patients who underwent nICT followed by surgery from February 2020 to April 2022 were included in the study. The dynamic change of inflammatory indexes was compared at baseline, after two cycles of nICT and postoperative one month. Least absolute shrinkage and selection operator (LASSO) regression was performed to avoid collinearity and identify key indexes, with SITI constructed. After univariate and multivariate stepwise forward logistic analyses, a nomogram for pCR prediction was developed. Results: 41(27.9%) patients achieved pCR among 147 resectable LA-ESCC patients received nICT. Compared with baseline, most inflammatory indexes were significantly decreased at postoperative one month. 5 key indexes were identified and then a predictive index named SITI was constructed. The result showed that lower SITI and earlier clinical tumor node metastasis (cTNM) stage were more likely to achieve pCR. The nomogram for pCR prediction had excellent discrimination performance (C-index = 0.791). Conclusion: The SITI is an independent predictor for pCR in resectable LA-ESCC patients received nICT. To our knowledge, our nomogram is the first model using systemic inflammation-tumor markers for pCR prediction and may be a promising predictor to effectively differentiate pCR for nICT in LA-ESCC patients. Keywords: esophageal squamous cell carcinoma, neoadjuvant therapy, immunotherapy, pathologic complete response, inflammation, nomogram Esophageal cancer is a global health challenge with high cancer incidence and cancer-related death worldwide. 1,2 The majority of esophageal cancer cases are found in Asia, with 49% in China. Esophageal squamous cell carcinoma (ESCC) is the most common pathological type in China. 3,4 Neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) plus surgery has become the preferred treatment for locally advanced esophageal squamous cell carcinoma (LA-ESCC), although the long-time survival for which is still unsatisfactory. 5–8 Recently, immunotherapy combined with chemotherapy has become the new standard of first-line treatment for advanced ESCC, 9–13 which has brought widespread attention to attempts at neoadjuvant immunochemotherapy (nICT) for resectable LA-ESCC. At present, nICT is recommended for patients with LA-ESCC in clinical studies, and its safety and clinical benefit was observed. 14–17 Pathological complete response (pCR) is considered to be an important therapeutic effect of neoadjuvant therapy and a good surrogate marker of postoperative survival. However, studies regarding reliable pCR prediction in resectable LA-ESCC patients receiving nICT are lacking. Although the expression of programmed cell death ligand-1 (PD-L1), tumor mutation load, microsatellite stability, and T cell function have been reported to be associated with immunotherapy efficacy, 18,19 these tests remain difficult for some patients due to medical conditions and economic constraints. Therefore, it is of great significance to find more affordable, effective and accurate indicators and establish more practical predictive models for personalized pCR prediction for patients with LA-ESCC. Several inflammatory indexes have been reported to be associated with pCR and prognosis after neoadjuvant therapy for esophageal cancer, such as lymphocyte (LY), 20,21 neutrophil to lymphocyte ratio (NLR), 21,22 platelet to lymp -Abstract Truncated-
immunology